DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,919,467 B2 Ramakrishna Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,919,467 B2 Ramakrishna Et Al US0079 19467B2 (12) United States Patent (10) Patent No.: US 7,919,467 B2 Ramakrishna et al. (45) Date of Patent: Apr. 5, 2011 (54) CYTOTOXICT-LYMPHOCYTE-INDUCING OTHER PUBLICATIONS IMMUNOGENS FOR PREVENTION, Smith et al. (Nature Biotechnology 15:1222-1223 (1997)).* TREATMENT, AND DIAGNOSIS OF CANCER Brenner (Trends in Genetics 15:132-133 (1999)).* Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).* (75) Inventors: Venky Ramakrishna, Riegelsville, PA Dennis (Nature 442:739-741 (2006)).* (US); Mark M. Ross, Charlottesville, Cespcles et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).* VA (US); Ramila Philip, Ivyland, PA Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)).* (US); Lorraine H. Keller, Pipersville, clinicaltrials.gov search (ImmunoVaccine Technologies, Inc., pp. PA (US) 1-3; Jan. 29, 2011).* Adachiet al., 1992, Nucleic Acids Research, vol. 20, pp. 5297-5303. (73) Assignee: Immunotope, Inc., Doylestown, PA Boon, T. et al., Ann. Rev. Immunol. 12:337-365 (1994). Celluzzi, C. M. et al., J. Exp. Med., 183:283-287 (1996). (US) European Search Report, dated Jan. 26, 2005. Gilboa, E., Immunity, 11:263-270 (1999). (*) Notice: Subject to any disclaimer, the term of this Gluzman, Cell, 23:175 (1981). patent is extended or adjusted under 35 Harding, C. H. III, Eur, J. Immunol. 22:1865-1869 (1992). U.S.C. 154(b) by 560 days. Henderson R. A. etal, DirectIdentification of an Endogenous Peptide Reognized by Multiple HLA-A2.1 Specific Cytotoxic T Cells, (21) Appl. No.: 11/426,161 National Academy of Sciences, vol. 90, pp. 10275-10279 (Nov. 1993). (22) Filed: Jun. 23, 2006 Hogan, K. T. et al., The peptide Recognized by HLAA68.2-Re stricted, Squamous Cell Carcinoma of the Lung-Specific Cytotoxic T (65) Prior Publication Data Lymphocytes is Derviced froma Mutated Elongation Factor 2 Gene, American Association for Cancer Research, vol. 58, No. 22, pp. US 2008/O2O7497 A1 Aug. 28, 2008 5144-5150 (Nov. 15, 1998). Hunt, D. F. et al., Proc. Natl. Acad. Sci. USA, 83:6233-6237 (1986). Related U.S. Application Data Hunt, D. F. et al., Science, 255:1261-1263 (1992). Jacob, L. et al., Int. J. Cancer, 71:325-332 (1997). (63) Continuation-in-part of application No. 10/006, 177, Joslyn G. et al., Identification of Deletion Mutations and Three New filed on Dec. 4, 2001, now Pat. No. 7,083,789. Genes at the Familial Polyposis Locus, Cell, vol. 66, No. 3, pp. (60) Provisional application No. 60/251,022, filed on Dec. 604-614 (1991). Kabat et al., J. Biol. Chem. 252:6609-6616 (1977). 4, 2000, provisional application No. 60/256,824, filed Kinzler, K.W. et al., Identification of FAP Locus Genes from Chro on Dec. 20, 2000. mosome 5.Q21, Science, vol. 253, No. 5020, pp. 661-665 (1991). Lauritzsen et al (International Journal of Cancer, 1998, vol. 78, pp. (51) Int. C. 216-222. A6 IK38/6 (2006.01) Ljunggren, H. G. et al., Nature, 346:476-480 (1990). A6IP35/00 (2006.01) Loannides, C. G. et al., J. Immunol. 146:1700-1707 (1991). (52) U.S. Cl. ...................................................... S14/19.3 Mayordome, J. et al., Nat. Med., 1:1297-1302 (1995). (58) Field of Classification Search ................ 424/185.1 Moore, J. W. et al., Cell, 54.777-785 (1988). See application file for complete search history. North, R. J. et al., Infect. Immun., 67:2010-2012 (1999). Parkhurst, M. R. et al., J. Immunol. 157:2539-2548 (1996). Peiper, M. et al., Eur, J. Immunol. 27: 1115-1123 (1997). (56) References Cited Peoples, G.E. et al., Surgery, 114:227-234 (1993). Perez-Diez, A. et al., Cancer Res., 58:5305-5309 (1998). U.S. PATENT DOCUMENTS Plebanski et al., Eur, J. Immunol., 25:1783 (1995). 4,235,871 A 11/1980 Papahadjopoulos et al. Posneft, D. N. et al., J. Biol. Chem., 263:1719-1725 (1988). 4,501,728 A 2f1985 Geho et al. Reddy, R. et al., J. Immunol Methods, 141: 157-163 (1991). 4,690,915 A 9/1987 Rosenberg Riddell, S. R. et al., J. Immunol. Methods, 128:189-201 (1990). 4,722,848 A 2f1988 Paolette et al. Riddell, S. R. et al., Science, 257:238-241 (1992). 4,837,028 A 6, 1989 Allen 4,844,893 A 7, 1989 Honski et al. Rock, K. L. et al., Ann. Rev. Immunol., 17:739-779 (1999). 5,019,369 A 5, 1991 Presant et al. Rosenberg, S.A. et al., A New Era for Cancer Immunotherapy Based 5,635,363 A 6, 1997 Altman et al. on the Genes that encode cancer antigens, Immunity, Cell Press, US, 5,645,994 A 7/1997 Huang et al. vol. 10, No. 3, pp. 281-287 (Mar. 1999). 5,747,269 A 5/1998 Rammensee et al. 5,763,219 A 6/1998 Keyomarsi (Continued) 5,972,643 A 10, 1999 Lobanenkov 6,140,464 A 10, 2000 Pfreundschuh et al. Primary Examiner — Lynn Bristol 6,168,804 B1* 1/2001 Samuel et al. ................ 424/450 (74) Attorney, Agent, or Firm — Ballard Spahr LLP 6,548,064 B1 4/2003 Tureci et al. 6,867.283 B2 3/2005 Barnea 7,083,789 B2 8/2006 Ramakrishna et al. (57) ABSTRACT 7,087,712 B1 8, 2006 Brossart et al. The present invention relates to compositions and methods 7,270,819 B2 9, 2007 Tureci et al. for the prevention, treatment, and diagnosis of cancer, espe 2004/0236091 A1* 11, 2004 Chicz et al. .................. 536,235 cially carcinomas, Such as ovarian carcinoma. The invention FOREIGN PATENT DOCUMENTS discloses peptides, polypeptides, and polynucleotides that WO 93.10814 6, 1993 can be used to stimulate a CTL response against cancer. WO WO O2/46416 6, 2002 WO WO 2007/081680 7/2007 14 Claims, No Drawings US 7,919.467 B2 Page 2 OTHER PUBLICATIONS Huynh Khanh D et al., “BCor, a novel corepressor involved in BCL-6 repression' Genes and Development, vol. 14, No. 14, Jul. 15, 2000, Rosenberg, S. A. et al., N. Engl. J. Med., 319:1676-1680 (1988). pp. 1810-1823. Rosenberg, S. A. et al., Nat. Med., 4:321-327 (1998). Ramakrishna V et al., “Generation and Phenotypic Characterization Sarma et al., Journal of Experimental Medicine, 1999, vol. 189, pp. of New Human Ovarian Cancer Cell Lines With the Identification of 811-820. Antigens Potetially Recognizable by HLA-Restricted Cytotoxic T Cells' Journal of Cancer, John Wiley & Sons, Inc., United States, Schendel, D. J. et al., J. Immunol. 151:4209-4220 (1993). Switzerland, Germany vol. 73, No. 1, Sep. 26, 1997, pp. 143-150. Sherman, LA et al., 1998, Critical Reviews in Immunol., 18(1-2): EPO 019995455.1 Office Action (Feb. 29, 2008). 47-54. EPO 019995455.1 Result of Consultation (Aug. 13, 2009). Slingluff, C. L. Jr. et al., Cancer Res., 54:2731-2737 (1994). EPO 019995455.1 Minutes of Oral Proceedings (Oct. 11, 2010). Slingluff, C. L. Jr. et al., J. Immunol. 150:2955-2963 (1993). EPO 019995455.1—Decision to Refuse a European Patent Applica Slovin, S.F. et al., J. Immunol., 137:3042-3048 (1987). tion (Nov. 10, 2010). Tsai-Pflugfelder et al., Cloning and sequencing of cDNA encoding Arceci, Journal of Molecular Medicine, 76, 1998. human DNA topoisomerase II and localization of the gene to chro Benjamini et al (edited by); Immunology: A Short Course, p. 40, mosome region 17q21-22, Proc. Natl. Acad. Sci. USA. vol. 85, pp. 1991. 7177-7181 (1988). Bodey et al; Anticancer Research, 20, 2000. Tuting, T. et al., J. Immunol. 160: 1139-1147 (1998). Boon, Advances in Cancer Research, 58, 1992. Voet et al., Biochemistry, John Wiley & Sons, 1990, pp. 60-63 only. Cox et al., Science, 264, 1994. Walter, E. A. et al., N. Engl. J. Med., 333:1038-1044 (1995). Deppenmeier etal (SwissProt, Accession No. Q8PWE3, version 1, p. Watts, C., Ann. Rev. Immunol. 15:821-850 (1997). 1, available Oct. 1, 2002). Wolfel, T. et al., Int. J. Cancer, 54:636-644 (1993). Elgertet al., Immunology: Understanding the Immune System, 1996. Yasumura, S. et al., Cancer Res., 53:1461-1468 (1993). Lollini et al. Curr. Cancer Drug Targets 5(3), 2005. Yewdell, J. W. et al., Ann. Rev. Immunol., 17:51-88 (1999). Lollini et al., Trends Immunol. 24(2); (2003). Yoshino, I. et al., cancer Res., 54:3387-3390 (1994). National Cancer Institute (Cancer Facts, Fact Sheet 5, 1998. Zeh, H. J. III et al., Hum. Immunol. 39:79-86 (1994). Rongcun, Yet al., Journal of Immunology, 163, 1999. Zitvogel, L. et al., J. Exp. Med., 183:87-97 (1996). Wang, et al., Exp. Opin. Biol. Ther. 1(2), 2001. Hengstler et al. (1999) Cancer Research 59,3206-3214. Watson et al. (edited by), Molecular Biology of the Gene, p. 43 Imal et al. (1995) Clinical Cancer Research 1, 417-424. (1988). Mosolits et al. (1999) Cancer Immunol. Immunother, 47, 315-320 Zhou et al., J. Exp. Med., 183:87–97 (1996). (first page only). PCT/US2001/047290 ISR (Date of Report Sep. 14, 2005). Fisk Bryan et al., “Identification of naturally processed human PCT/US2007/077250 ISR (Date of Report Aug. 21, 2008). ovarian peptides recognized by tumor-associated CD8+ cytotoxic T PCT/US2007/024787 ISR (Date of Report Sep. 18, 2008). lymphocytes' Cancer Research, vol. 57, No. 1, 1997, pp. 87-93. EPO 10178439.5–Search Report (Feb. 3, 2011). Fisk B et al., "Identification of an Immunodominant Peptide of HER Schirle, Markus, et al.; Identification of tumor-associated MHC class 2/neu Protooncogene Recognized by Ovarian Tumor-specific I ligands by a novel T cell-independent approach; European Journal Cytotoxic T Lymphocyte Lines' The Journal of Experimental of Immunology, Aug.
Load more

Recommended publications
  • Alpha Actinin 4: an Intergral Component of Transcriptional
    ALPHA ACTININ 4: AN INTERGRAL COMPONENT OF TRANSCRIPTIONAL PROGRAM REGULATED BY NUCLEAR HORMONE RECEPTORS By SIMRAN KHURANA Submitted in partial fulfillment of the requirements for the degree of doctor of philosophy Thesis Advisor: Dr. Hung-Ying Kao Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY August, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of SIMRAN KHURANA ______________________________________________________ PhD candidate for the ________________________________degree *. Dr. David Samols (signed)_______________________________________________ (chair of the committee) Dr. Hung-Ying Kao ________________________________________________ Dr. Edward Stavnezer ________________________________________________ Dr. Leslie Bruggeman ________________________________________________ Dr. Colleen Croniger ________________________________________________ ________________________________________________ May 2011 (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. TABLE OF CONTENTS LIST OF TABLES vii LIST OF FIGURES viii ACKNOWLEDEMENTS xii LIST OF ABBREVIATIONS xiii ABSTRACT 1 CHAPTER 1: INTRODUCTION Family of Nuclear Receptors 3 Mechanism of transcriptional regulation by co-repressors and co-activators 8 Importance of LXXLL motif of co-activators in NR mediated transcription 12 Cyclic recruitment of co-regulators on the target promoters 15 Actin and actin related proteins (ABPs) in transcription
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • NVND-2019 Book
    2nd International Conference on Neurovascular and Neurodegenerative Diseases October 28-30 2019 Media Partner Venue Paris Marriott Charles de Gaulle Airport Hotel 5 Allee du Verger, Zone Hoteliere Roissy en France, 95700 France Day- 1 Monday | October 28, 2019 Keynote Presentations Cerebrovascular Lesions in Pick Complex Diseases: A Neuropathological Study with a 7.0-tesla Magnetic Resonance Imaging Jacques De Reuck Université Lille 2, INSERM U1171, Degenerative & Vascular Cognitive Disorders, CHR Lille, France Abstract Introduction: Pick complex refers to a spectrum of diseases that have in common the presence of tau inclusions. The main neuropathological phenotypes comprise tau-frontotemporal lobar degeneration (Tau-FTLD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). The present neuropathological study investigates their incidence of cerebrovascular lesions. Material and Methods: seventy patients underwent an autopsy and post-mortem MRI. The brains consisted of 14 with Tau-FTLD, 22 with PSP, 6 with CBD and 28 controls, who had no history of a brain disease. A whole coronal section of a cerebral hemisphere, at the level of the mamillary body, was taken for the semi-quantitative evaluation of the small cerebrovascular lesions such as white matter changes (WMCs), cortical micro-bleeds (CoMBs), and cortical micro-infarcts (CoMIs). In addition the severity and the distribution of WMCs, CoMIs and CoMBs were examined with 7.0-tesla MRI on three coronal sections of a cerebral hemisphere. Results: on neuropathological examination severe WMCs and more CoMBs are observed in Tau-FTLD, while the latter are also more frequent in CBD. The MRI examination shows that severe WMCs are present in the frontal sections not only of the Tau-FTLD but also to a lesser degree of the PSP and CBD brains.
    [Show full text]
  • Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases
    Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Olivares, Ana Maria, Oscar Andrés Moreno-Ramos, and Neena B. Haider. 2015. “Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases.” Journal of Experimental Neuroscience 9 (Suppl 2): 93-121. doi:10.4137/JEN.S25480. http:// dx.doi.org/10.4137/JEN.S25480. Published Version doi:10.4137/JEN.S25480 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320246 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Journal name: Journal of Experimental Neuroscience Journal type: Review Year: 2015 Volume: 9(S2) Role of Nuclear Receptors in Central Nervous System Running head verso: Olivares et al Development and Associated Diseases Running head recto: Nuclear receptors development and associated diseases Supplementary Issue: Molecular and Cellular Mechanisms of Neurodegeneration Ana Maria Olivares1, Oscar Andrés Moreno-Ramos2 and Neena B. Haider1 1Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. 2Departamento de Ciencias Biológicas, Facultad de Ciencias, Universidad de los Andes, Bogotá, Colombia. ABSTRACT: The nuclear hormone receptor (NHR) superfamily is composed of a wide range of receptors involved in a myriad of important biological processes, including development, growth, metabolism, and maintenance.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Kinesin Family Member 6 (Kif6) Is Necessary for Spine Development in Zebrafish 8 9 10 11 12 Jillian G
    Page 1 of 40 Developmental Dynamics 1 2 3 4 5 6 7 Kinesin family member 6 (kif6) is necessary for spine development in zebrafish 8 9 10 11 12 Jillian G. Buchan1, Ryan S. Gray2, John M. Gansner6, David M. Alvarado3, Lydia Burgert4, 13 14 Jonathan D. Gitlin7, Christina A. Gurnett3,4,5, Matthew I. Goldsmith1,4,* 15 16 17 Departments of 1Genetics, 2Developmental Biology, 3Orthopaedic Surgery, 4Pediatrics, 18 5 6 19 Neurology, Washington University School of Medicine, St. Louis, MO, 63110; Dana-Farber 20 Cancer Institute, Boston, MA, 02215; 7Eugene Bell Center for Regenerative Biology, Marine 21 Biological Laboratory, Woods Hole, MA, 02543 22 23 24 25 26 *Corresponding author: Matthew I. Goldsmith, MD 27 28 Department of Pediatrics 29 Washington University School of Medicine 30 [email protected] 31 660 S Euclid Ave, Campus Box 8208 32 St Louis, MO 63110 33 Phone: (314) 286-2769 34 35 Fax: (314) 286-2784 36 37 38 39 Running Title: Kif6 in zebrafish spine development 40 41 Keywords: kinesin, scoliosis, Danio rerio 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Developmental Dynamics Page 2 of 40 1 2 3 ABSTRACT 4 5 6 Background: Idiopathic scoliosis is a form of spinal deformity that affects 2-3% of children and 7 8 results in curvature of the spine without structural defects of the vertebral units. The 9 10 11 pathogenesis of idiopathic scoliosis remains poorly understood, in part due to the lack of a 12 13 relevant animal model.
    [Show full text]
  • Anti-Testicular Receptor 2 (TR2) (Rabbit) Antibody - 100-401-E45
    Anti-Testicular Receptor 2 (TR2) (Rabbit) Antibody - 100-401-E45 Code: 100-401-E45 Size: 100 µL Product Description: Anti-Testicular Receptor 2 (TR2) (Rabbit) Antibody - 100-401-E45 Concentration: Titrated value sufficient to run approximately 10 mini blots. PhysicalState: Liquid Label Unconjugated Host Rabbit Gene Name NR2C1 Species Reactivity mouse, human, rat Storage Condition Store vial at -20° C prior to opening. This product is stable at 4° C as an undiluted liquid. For extended storage, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Dilute only prior to immediate use. Synonyms Nuclear receptor subfamily 2 group C member 1, Orphan nuclear receptor TR2, mTR2 Application Note Anti-Testicular Receptor 2 (Rabbit) antibody is suitable for use in Western Blots. Anti-Testicular Receptor 2 antibodies are specific for the ~64 kDa TR2 protein in Western blots of testes and nuclear extracts from MEL cell lines. Researchers should determine optimal titers for applications that are not stated below. Background TR2 antibody detects Testicular receptor 2 (TR2), which is a member of the orphan nuclear receptor family. It is widely expressed at a low level throughout the adult testis. TR2 represses transcription and binds DNA directly interacting with HDAC3 and HDAC4 via DNA-binding domains. TR2 has also been implicated in regulation of estrogen receptor activity in mammary glands. In addition, TR2 has recently been shown to form a heterodimer with TR4 that can bind to the direct repeat 6 element of the hepatitis B virus (HBV) enhancer II region thus suppressing HBV gene expression.
    [Show full text]
  • Towards Relating the Evolution of the Gene Repertoire in Mammals to Tissue Specialisation
    Towards Relating the Evolution of the Gene Repertoire in Mammals to Tissue Specialisation Shiri Freilich Wolfson College This dissertation is submitted to the University of Cambridge for the degree of Doctor of Philosophy 21 December 2006 To Leon, who was the wind blowing in my sails, in the deep blue sea of this journey of ours. This Thesis is the result of my own work and includes nothing which is the outcome of work done in collaboration except where specifically indicated in the text. This Thesis does not exceed the specified length limit of 300 pages as defined by the Biology Degree Committee. This Thesis has been typeset in 12pt font according to the specifications defined by the Board of Graduate Studies and the Biology Degree Committee. 3 Summary: Towards Relating the Evolution of the Gene Repertoire in Mammals to Tissue Specialisation The sequencing efforts of recent years have provided a rich source of data for investigating how gene content determines similarity and uniqueness in a species’ phenotype. Work described in this PhD Thesis attempts to relate innovations in the gene repertoire along the mammalian lineage to the most obvious phenotypic characteristic of animals: the appearance of highly differentiated tissue types. Several different approaches, outlined below, have been followed to address some aspects of this problem. Initially, a comprehensive study of the pattern of expansion of the complement of enzymes in various species was performed in order to obtain a better view of the principles underlying the expansion of the gene repertoire in mammals. Although several studies have described a tendency toward an increase in sequence redundancy in mammals, not much is known about the way such sequence redundancy reflects functional redundancy.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Antigen-Specific Memory CD4 T Cells Coordinated Changes in DNA
    Downloaded from http://www.jimmunol.org/ by guest on September 24, 2021 is online at: average * The Journal of Immunology The Journal of Immunology published online 18 March 2013 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2013/03/17/jimmun ol.1202267 Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells Shin-ichi Hashimoto, Katsumi Ogoshi, Atsushi Sasaki, Jun Abe, Wei Qu, Yoichiro Nakatani, Budrul Ahsan, Kenshiro Oshima, Francis H. W. Shand, Akio Ametani, Yutaka Suzuki, Shuichi Kaneko, Takashi Wada, Masahira Hattori, Sumio Sugano, Shinichi Morishita and Kouji Matsushima J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Author Choice option Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Freely available online through http://www.jimmunol.org/content/suppl/2013/03/18/jimmunol.120226 7.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Author Choice Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 24, 2021. Published March 18, 2013, doi:10.4049/jimmunol.1202267 The Journal of Immunology Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells Shin-ichi Hashimoto,*,†,‡ Katsumi Ogoshi,* Atsushi Sasaki,† Jun Abe,* Wei Qu,† Yoichiro Nakatani,† Budrul Ahsan,x Kenshiro Oshima,† Francis H.
    [Show full text]
  • Identification of ROBO2 As a Potential Locus Associated with Inhaled
    Journal of Personalized Medicine Article Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma Natalia Hernandez-Pacheco 1,2,3,*,†, Mario Gorenjak 4 , Jiang Li 5 , Katja Repnik 4,6, Susanne J. Vijverberg 7,8,9, Vojko Berce 4,10 , Andrea Jorgensen 11, Leila Karimi 12 , Maximilian Schieck 13,14, Lesly-Anne Samedy-Bates 15,16, Roger Tavendale 17, Jesús Villar 3,18,19 , Somnath Mukhopadhyay 17,20, Munir Pirmohamed 21 , Katia M. C. Verhamme 12, Michael Kabesch 13, Daniel B. Hawcutt 22,23, Steve Turner 24 , Colin N. Palmer 17, Kelan G. Tantisira 5,25, Esteban G. Burchard 15,16, Anke H. Maitland-van der Zee 7,8,9 , Carlos Flores 1,3,26,27 , Uroš Potoˇcnik 4,6,*,‡ and Maria Pino-Yanes 2,3,27,‡ 1 Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Carretera General del Rosario 145, 38010 Santa Cruz de Tenerife, Spain; cfl[email protected] 2 Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, Avenida Astrofísico Francisco Sánchez s/n, Faculty of Science, Apartado 456, 38200 San Cristóbal de La Laguna, Spain; [email protected] 3 CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Avenida de Monforte de Lemos, 5, 28029 Madrid, Spain; [email protected] 4 Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia; [email protected] (M.G.); [email protected] (K.R.); [email protected]
    [Show full text]
  • Supplementary Data
    Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type
    [Show full text]